Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2003)Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer J Natl Cancer Inst 95 142-153

[3] Siegel RL(2018)Differences in breast cancer survival by molecular subtypes in the United States Cancer Epidemiol Biomarkers Prev 27 619-626

[4] Laversanne M(2012)Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial Breast 21 27-33

[5] Soerjomataram I(2009)Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 5529-5537

[6] Jemal A(2009)Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 5538-5546

[7] Bray F(2018)First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase ii trial J Clin Oncol 36 2826-2835

[8] Konecny G(2012)Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109-119

[9] Pauletti G(2013)Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 14 461-471

[10] Pegram M(2012)Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study J Clin Oncol 30 2585-2592

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2003)Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer J Natl Cancer Inst 95 142-153

[3] Siegel RL(2018)Differences in breast cancer survival by molecular subtypes in the United States Cancer Epidemiol Biomarkers Prev 27 619-626

[4] Laversanne M(2012)Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial Breast 21 27-33

[5] Soerjomataram I(2009)Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 5529-5537

[6] Jemal A(2009)Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 5538-5546

[7] Bray F(2018)First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase ii trial J Clin Oncol 36 2826-2835

[8] Konecny G(2012)Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109-119

[9] Pauletti G(2013)Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 14 461-471

[10] Pegram M(2012)Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study J Clin Oncol 30 2585-2592